WAVE Life Sciences
733 Concord Avenue
Cambridge
Massachusetts
02138
United States
Tel: 1-617-949-2900
Fax: 1-617-949-2901
Website: http://wavelifesciences.com/
Email: info@wavelifesci.com
About WAVE Life Sciences
WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW WAVE LIFE SCIENCES:
Tweets by Wave Life Sciences
128 articles with WAVE Life Sciences
-
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
3/29/2023
Wave Life Sciences Ltd. announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on Monday, April 3, 2023 at 2:10 p.m. ET.
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/22/2023
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
-
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
3/2/2023
Wave Life Sciences Ltd. announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 22, 2023, to discuss the company’s fourth quarter and full year 2022 financial results and provide a business update.
-
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
2/9/2023
Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the SVB Securities Global Biopharma Conference at 10:00 a.m. ET on Thursday, February, 16, 2023.
-
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
12/19/2022
Wave Life Sciences Ltd. announced today a positive update from the initial cohort of the Phase 1b/2a proof-of-concept study of WVE-N531 in three boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.
-
GSK bolstered its position in the oligonucleotide therapeutics space through a four-year collaboration with Wave Life Sciences valued at up to $3.3 billion.
-
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
12/13/2022
Wave Life Sciences Ltd. today announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing program targeting alpha-1 antitrypsin deficiency (AATD), WVE-006.
-
Huntington’s disease might just top the list of intractable neurodegenerative diseases. BioSpace spoke with the field's foremost experts about the challenges and how to overcome them.
-
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
11/10/2022
Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced financial results for the third quarter ended September 30, 2022 and provided a business update.
-
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
11/9/2022
Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on Wednesday, November 16, 2022, at 3:35 p.m. ET.
-
Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
11/3/2022
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 10, 2022, to discuss the company’s third quarter 2022 financial results and provide a business update.
-
Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
10/3/2022
Wave Life Sciences Ltd. announced it will highlight oligonucleotide chemistry advancements from the company’s PRISMTM discovery and drug development platform at upcoming scientific conferences.
-
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
9/27/2022
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan’s 6th Annual Genetic Medicines Conference.
-
Wave Life Sciences presented promising early data from its Phase Ib/IIa SELECT-HD trial in Huntington’s disease with evidence of biomarker improvements.
-
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
9/20/2022
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced a positive update to the ongoing Phase 1b/2a SELECT-HD clinical trial of WVE-003, the company’s clinical candidate for Huntington’s disease (HD).
-
Wave Life Sciences to Host Analyst and Investor Virtual Event
9/16/2022
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced it will hold an analyst and investor webcast on Wednesday, September 28, 2022.
-
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
8/11/2022
Wave Life Sciences Ltd. today announced financial results for the second quarter ended June 30, 2022 and provided a business update.
-
Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022
7/28/2022
Wave Life Sciences Ltd. (Nasdaq: WVE), announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 11, 2022, to discuss the company’s second quarter 2022 financial results and provide a business update.
-
uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company's president of R&D, Dr. Ricardo Dolmetsch.
-
Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
6/14/2022
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of an underwritten offering (the “Offering”) of 25,464,483 of its ordinary shares at an offering price of $2.15 per ordinary share, and, to RA Capital Management, L.P. in lieu of ordinary shares.